索利那新加坦索罗辛治疗膀胱过度活动症的疗效分析

Efficacy of solifenacin with or without tamsulosin in patients with overactive bladder

目的探讨索利那新加坦索罗辛治疗膀胱过度活动症（OAB）的疗效。方法OAB患者53例，男15例，女38例。年龄29～72岁，平均43岁。随机分为2组，A组为单用索利那新组（27例），B组为索利那新加用坦索罗辛组（26例）。服药方法：索利那新5mg／d，坦索罗辛0．2mg／a。连续14d后随访，再进行OABSS评分。结果A组患者治疗前后尿急评分分别为（3．3±1．0）与（1．9±0．6）分，OABSS评分分别为（10．8±4．9）与（5．2±1．8）分；B组患者治疗前后尿急评分分别为（3．6±1．0）与（0．9±0．1）分，OABSS评分分别为（10．7±1．9）与（3．9±1．8）分，2组治疗前后差异均有统计学意义（P〈0．05），2组治疗后尿急评分和OABSS评分差异有统计学意义（P〈0．05）。结论索利那新加用坦索罗辛可以有效缓解OAB患者的尿急症状并降低OABSS评分，索利那新加用坦索罗辛疗效好于单用索利那新。

Objective To evaluate the efficacy of sollfenacin with or without tamsulosin in patients with overactive bladder （OAB）. Methods Fifty-three patients with OAB were randomly divided into two groups （group A 27 patients, group B 26 patients）. The patients received either solifenacin 5 rag/day in group A or combined with Tamsulosin 0.2 rag/day in group B for two weeks. During the treatent period all the patients recorded voiding and adverse events in a diary. The symptoms of urgency, frequency, inconti- nence were evaluated by OABSS scores at the begining and end of the therapy period. The results of the efficacy and safety were analyzed by using SPSS 13.0. Results The OABSS scores at the begining and end for the two groups were significantly different （P 〈 0.01 ）. In both groups the efficacy was obvious. The OABSS scores at the end of the therapy between group A and B were significantly different （P 〈 0.05）. The efficacy of group B was better than that of group A. Conclusion The efficacy of solifenacin combined with tamsulosin was better than solifenaein alone in OAB.